Related Experiment Videos
The monosialoganglioside, GM1, reduces neurologic injury associated with hypothermic circulatory arrest
J M Redmond1, A M Gillinov, M E Blue
1Johns Hopkins Medical Institutions, Baltimore, MD.
Insights
Monosialoganglioside GM1 administration significantly reduced brain injury and improved neurological function in dogs undergoing prolonged hypothermic circulatory arrest (HCA). These findings suggest GM1
Area of Science:
- Neuroscience
- Cardiovascular Surgery
- Pharmacology
Background:
- Prolonged hypothermic circulatory arrest (HCA) can lead to neurologic injury.
- Calcium-dependent glutamate excitotoxicity (GE) is a potential mechanism for HCA-induced brain damage.
- Monosialoganglioside GM1 demonstrates in vitro efficacy in mitigating GE under metabolic stress.
Purpose of the Study:
- To investigate the neuroprotective potential of gangliosides against HCA-induced brain injury.
- To test the hypothesis that GM1 can prevent brain damage following prolonged HCA.
Main Methods:
- A canine model subjected to 2 hours of HCA at 18°C.
- Group 1: Pretreated and infused with GM1; Group 2: Received vehicle control.
- Neurological assessment using a standardized scale, followed by post-mortem histological and autoradiographic examination of brain tissue.
Main Results:
- GM1-treated dogs exhibited significantly lower neurodeficit scores (4.2% vs 38.4%) and reduced neuronal injury (11.3 vs 48.3) compared to controls.
- Preservation of neuronal glutamate receptor expression was observed exclusively in the GM1-treated group.
- Statistical significance (p < 0.001) was achieved for both neurological function and neuronal injury outcomes.
Conclusions:
- The study provides evidence supporting the role of glutamate excitotoxicity in HCA-induced brain injury.
- Monosialogangliosides, specifically GM1, demonstrate neuroprotective capabilities during prolonged hypothermic circulatory arrest.
- GM1 represents a potential therapeutic agent for preventing brain damage in HCA scenarios.
Background:
Neurologic injury associated with prolonged hypothermic circulatory arrest (HCA) may be mediated by calcium-dependent glutamate excitotoxicity (GE). The monosialoganglioside GM1 has been shown in vitro to limit GE in conditions of metabolic stress. To test the hypothesis that gangliosides can prevent HCA-induced brain injury, GM1 was used in a canine model of HCA.
Methods:
Twelve male dogs were placed on closed-chest cardiopulmonary bypass, subjected to 2 hours of HCA at 18 degrees C, and rewarmed to 36 degrees to 37 degrees C on closed-chest cardiopulmonary bypass. All were mechanically ventilated and monitored for 20 hours before extubation and survived for 3 days. Group 1 dogs (n = 6) were pretreated with GM1, 30 mg/kg/24hr for 3 days before HCA, and received continuous infusion of GM1 during the procedure and 30 mg/kg/24hr for 3 days after HCA. Group 2 dogs (n = 6) received vehicle only. With a species-specific behavior scale that yielded a neurodeficit score ranging from 0% (normal) to 100% (brain dead), all animals were neurologically assessed every 12 hours. After death at 72 hours, brains were examined by glutamate receptor autoradiography and by histologic examination for patterns of selective neuronal necrosis and were scored blindly from 0 (normal) to 100 (severe injury).
Results:
Group 1 dogs had better neurologic function compared with group 2 (neurodeficit score, 4.2% +/- 3% vs 38.4% +/- 8%; p < 0.001) and had less neuronal injury (11.3 +/- 3 vs 48.3 +/- 9, p < 0.001). Densitometric receptor autoradiography revealed preservation of neuronal glutamate receptor expression in group 1 only.
Conclusions:
These results provide evidence of a role for GE in the development of HCA-induced brain injury and suggest that monosialogangliosides may have a neuroprotective capacity in prolonged periods of HCA.